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ABSTRACT 
Brain regions affected by Alzheimer's disease display well-recognized early neuropathological features in the 
endo-lysosomal and autophagy systems of neurons, including enlargement of endosomal compartments, 
progressive accumulation of autophagic vacuoles, and lysosomal dysfunction. Although the primary causes of 
these disturbances are still under investigation, a growing body of evidence suggests that the amyloid precursor 
protein (APP) intracellular C-terminal fragment-β (C99), generated by cleavage of APP by BACE1, is the 
primary cause of the endosome enlargement in AD and the earliest initiator of synaptic plasticity and long-term 
memory impairment. The aim of the present study was to evaluate the possible relationship between the endo-
lysosomal degradation pathway and autophagy on the proteolytic processing and turnover of C99. Herein, we 
show that pharmacological treatments that either inhibit autophagosome formation or block the fusion of 
autophagosomes to endo-lysosomal compartments caused an increase in C99 levels. We also show that 
inhibition of autophagosome formation by depletion of Atg5 led to higher levels of C99 and to its massive 
accumulation in the lumen of enlarged perinuclear, LAMP1-positive organelles. In contrast, activation of 
autophagosome formation, either by starvation or by inhibition of the mammalian target of rapamycin, 
enhanced lysosomal clearance of C99. Altogether, our results indicate that autophagosomes are key organelles 
to help avoid C99 accumulation preventing its deleterious effects. 
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INTRODUCTION 
Alzheimer's disease (AD) is the most common form of dementia. However, the identification of cell biological 
processes that cause AD remains a challenge. An important feature of brain regions of patients affected by AD 
is the accumulation of protein aggregates, namely tau tangles and amyloid-β (Aβ) plaques (1, 2). Aβ plaques 
are formed during the so-called amyloidogenic cleavage of the amyloid precursor protein (APP), which starts 
with the β-site APP cleaving enzyme 1 (BACE1) that generates a C-terminal fragment (CTF) named C99 (also 
called CTFβ; Fig. 1A). In contrast, nonamyloidogenic cleavage of APP by α-secretases generates a shorter CTF 
called C83 (also known as CTFα; Fig. 1A). The transmembrane domain of each CTF is further cleaved by γ-
secretase, which generates additional fragments: Aβ and AICDγ for C99, or p3 and AICDγ for C83 (3, 4) (Fig. 
1A). 
 
Although enhancement of amyloidogenic proteolytic processing of APP is considered crucial to AD 
pathogenesis, several reports indicate that defects in autophagy and the endo-lysosomal pathway of protein 
degradation are also critical (5-7). Autophagy can proceed via three mechanistically distinct pathways: 
macroautophagy, microautophagy and chaperone-mediated autophagy (8). Macroautophagy deficiency in mice 
brain results in neurodegeneration and is characterized by accumulation of ubiquitylated-protein aggregates (9), 
highlighting the importance of this pathway in neuronal homeostasis. Central to macroautophagy is the 
existence of transitory organelles called autophagosomes. Formation of autophagosomes occurs constitutively 
under normal nutrient conditions (9, 10), but is highly inducible by cellular stress such as amino acid starvation 
and inhibition of the key cell regulator mammalian target of rapamycin (mTOR) (11). Autophagosomes 
sequester cytoplasmic constituents and fuse with lysosomes to form autolysosomes, promoting degradation of 
sequestered content to recycle macromolecules, a process known as autophagy-flux (12). Ultrastructural studies 
of the brain of post mortem AD patients revealed that autophagic organelles including autophagosomes and 
autophagolysosomes gradually accumulate in dystrophic neurites, a neuropathological hallmark of AD, having 
important implications in Aβ peptide generation and neuronal survival in later stages of AD (13, 14). Although 
these findings explain the lower rates of protein degradation in AD neurons, it is still under study how to 
manipulate these pathways to increase protein clearance in neurons (15, 16). 
 
Autophagosomes can also fuse to pre-lysosomal endocytic organelles, such as late endosomes, also called 
multivesicular bodies (MVBs). Fusion of autophagosomes to MVBs generates a hybrid organelle called 
amphisome, which ultimately also fuses to lysosomes (17, 18). Biogenesis of MVBs involves the formation of 
intraluminal vesicles (ILVs), which requires the activity of the four, multi-subunit Endosome Sorting 
Complexes Required for Transport (ESCRTs 0 to III), collectively called the ESCRT machinery  
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(19, 20). Macroautophagy is abrogated in cells depleted of ESCRT subunits (21, 22), indicating a close 
interaction between these two pathways (10, 23). 
 
Intracellular trafficking of APP includes its targeting to endo-lysosomal membranes, either from the trans-Golgi 
network (TGN) sorted by the AP-4 adaptor complex (24, 25), or from the plasma membrane by endocytosis (26, 
27). Several studies have demonstrated that APP is normally incorporated into the ILVs of MVBs in a process 
dependent on the ESCRT machinery (26, 28, 29). However, it is still under debate if the MVB pathway prevents 
amyloidogenic processing of APP (28, 29), or increases Aβ production (26). Moreover, it is not clear how the 
ESCRT machinery affects both APP processing and CTFs levels, and whether its effects are a consequence of 
ILV formation or via autophagy-flux (21, 22) (30). Positive regulators of macroautophagy, such as SMER28 
(31) and the transcription factor EB (TFEB) (32) reduce the levels of APP and its CTFs. However, the 
mechanism that explains how autophagosomes impact the turnover of APP and its CTFs remains unknown. In 
the present study, we show that inhibition of either autophagosome formation or the fusion of autophagosomes 
with endo-lysosomal compartments caused a dramatic increase in CTFs levels. Surprisingly, microscopy 
analysis revealed that these CTFs accumulated in structures resembling ILVs of MVBs. In agreement with these 
findings, we show that activation of autophagosome formation, either by starvation or treatment with the mTOR 
inhibitor Torin-1, enhanced C99 lysosomal clearance. Therefore, we propose that autophagosomes are key 
organelles that connect with the MVB/lysosomal pathway for efficient turnover of CTFs. 
 
MATERIAL AND METHODS 
Chemical reagents and antibodies 
Bafilomycin A1 (BfaA1), Chloroquine (CQ), Earle's balanced salt solution (EBSS), N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), puromycin dihydrochloride, thapsigargin, 
and a cocktail of protease inhibitors were purchased from Sigma-Aldrich. Torin-1 was purchased from 
TOCRIS. The selective Vps34 inhibitor Vps34-IN1 was purchased from MedKoo Biosciences. We used the 
following mouse monoclonal antibodies: clone C4 anti-β-Actin, clone 51 anti-TSG101 and clone 3 anti-p62 
(BD Biosciences); clone WO2 anti-C99 fragment (Merck Millipore); clone H4A3 anti-LAMP1, clone H4B4 
anti-LAMP2 and clone H5C6 anti-CD63 (Developmental Studies Hybridoma Bank); and anti-GFP (Roche 
Applied Science). We used the following polyclonal antibodies: human anti-EEA1 (kindly provided by A. 
González, Pontificia Universidad Católica, Chile); rabbit anti-Cathepsin D (R&D Systems); rabbit anti-LC3 and 
rabbit anti-Atg5 (Cell Signaling Technology); and rabbit anti-APP (Invitrogen). HRP-conjugated secondary 
antibodies were purchased from Jackson ImmunoResearch, and 4',6-diamidino-2-phenylindole (DAPI) and 
fluorophore-conjugated secondary antibodies were from Life Technologies. 
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Cell culture, plasmids and generation of stable cell lines 
H4 human neuroglioma cells were obtained from the American Type Culture Collection. H4-derived cell lines 
were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% heat-inactivated fetal 
bovine serum (FBS) and penicillin/streptomycin (Life Technologies), in a 5% CO2 atmosphere at 37°C. The 
generation of H4 stable cell lines expressing either HA-tagged APP695-F/P-D/A-EGFP (APP-GFP) or C99-F/P-
D/A-EGFP (C99-GFP) was previously reported (33). Stably transfected cells were maintained in culture 
medium supplemented with 100 µg/ml G418. Cells were grown to subconfluence, and treated with drugs or 
lentiviral particles containing specific shRNAs for further western blot and immunofluorescence analysis. 
Nutrient starvation assays were performed in the presence of EBSS. 
 
RNA interference (RNAi) with siRNA 
A small interfering RNA (siRNA) designed to target human TSG101 (5'-CCU CCA GUC UUC UCU CGU C-
3') was purchased from Dharmacon (Lafayette, CO). siRNA transfections were carried out using the 
Oligofectamine reagent from Invitrogen (Camarillo, CA, USA), using similar conditions as described 
previously (25). 
 
RNA interference (RNAi) with shRNA 
We generated stable H4 neuroglioma cell lines with reduced Atg5 levels by introducing shRNA-containing 
lentiviral particles. shRNA sequences were cloned in the pLKO.1 vector, and a shRNA against the luciferase 
gene was used as a control. Lentiviral particles were generated by co-transfection of HEK293 cells with 
pLKO.1-shRNA constructs (1 µg), VSV-g (1 µg) and p∆8.9 (1 µg). Transfection was performed with 
Lipofectamine 2000 (Invitrogen) following the manufacture's instructions. Forty-eight hours post-transfection, 
the medium containing lentiviral particles was transferred to H4 cells at a 1:2 dilution in the presence of 8 µg/ml 
polybreen. After 24-h, cells were selected with 3 µg/ml of puromycin. pLKO.1 vectors were generated by The 
Broad Institute (Boston, MA; http://www.broad.mit.edu/genome_bio/trc/rnai.html). Stable H4 cells with 
reduced Atg5 levels were maintained in medium containing 3 µg/ml puromycin. We used a shRNA sequence 
against Atg5 that we selected and described previously (34). 
 
Preparation of protein extracts and western blotting 
Cells were washed in cold PBS and lysed at 4°C in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% Triton X-100) supplemented with a cocktail of protease inhibitors (Sigma-Aldrich). Lysates were 
cleared by centrifugation at 16,000 g for 20 min at 4°C, and protein concentration was determined with a 
protein assay solution (Bio-Rad Laboratories, Hercules, CA, USA). Samples with equivalent amount of protein 
were boiled for 5 min with Laemmli SDS-PAGE sample buffer, and analyzed by SDS-PAGE. Proteins were 
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electroblotted onto nitrocellulose membranes and incubated sequentially with primary and secondary antibodies 
for 1 h at room temperature, or overnight at 4ºC. Chemiluminescence protein detection was performed using 
Pierce Western Blotting Substrate (Thermo Scientific). β-actin was used as an internal loading control. 
 
Fluorescence microscopy 
Cells grown on glass coverslips were washed with PBS and fixed with 4% paraformaldehyde for 30 min at 
room temperature (RT). After fixation, cells were washed with PBS and permeabilized with 0.2% Triton X-100 
in PBS for 10 min at RT. Cells were incubated with the indicated primary antibodies diluted in 
immunofluorescence buffer (PBS containing 10% fetal bovine serum and 0.1% (w/v) saponin) for 45 min at 
37ºC. Coverslips were PBS-washed and incubated with the corresponding fluorophore-conjugated secondary 
antibody diluted in immunofluorescence buffer, for 30 min at 37ºC. For nuclei staining, cells were PBS-washed 
and incubated for 10 min at RT with 0.1 µg/ml DAPI. After the final wash, coverslips were mounted onto glass 
slides with Fluoromount-G (SouthernBiotech). Images of fixed cells were acquired with an AxioObserver.D1 
microscope equipped with a PlanApo 63× oil immersion objective (NA 1.4) and an AxioCam MRm digital 
camera (Carl Zeiss), using similar settings described previously (34), or with an Olympus FluoView FV1000 
scanning unit fitted on an inverted Olympus IX81 microscope equipped with a PlanApo 60× oil immersion 
objective (NA 1.4; Olympus), using similar settings as described previously (35). Alternatively, images of fixed 
cells were acquired by a DeltaVision OMX system for super-resolution by structured illumination microscopy, 
using similar settings as described previously (36) (37). For fluorescent signal quantification, 12-bit or 16-bit 
images (Z-stack, with 0.2 µm intervals) were acquired under identical settings avoiding signal saturation, and 
each image was corrected for the background. The corrected fluorescent signal in each cell of each image was 
used to determine the total integrated pixel intensity per cell area using Image J software 1.44o (Wayne 
Rasband, NIH, http://imagej.nih.gov). Colocalization analyses and estimation of the Pearson's correlation 
coefficient (38) were performed as described (35). 
 
Densitometric quantification and statistical analysis 
Quantification of immunoblot signals was performed using Image J software 1.44o. For each condition, protein 
bands were quantified from at least three independent experiments. Data analysis was performed using 
Microsoft Excel 2011 (Microsoft Corporation) or Prism 5.0 (GraphPad Software). Results were represented in 
graphs depicting the mean ± standard deviation. Statistical significance was determined by two-tailed, paired t-
test. P-values > 0.05 or ≤ 0.05 were regarded as not statistically significant or statistically significant, 
respectively. In the figures, P-values between 0.01 and 0.05 are indicated with one asterisk, P-values between 
0.001 and 0.01 are indicated with two asterisks and P-values less than 0.001 are indicated with three asterisks. 
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RESULTS 
Impaired lysosomal activity increases APP full-length and C99 levels 
Previous reports have demonstrated that the perturbation of lysosomal pH causes an increase in the levels of 
APP and CTFs (33, 39). However, it is not well defined if all CTFs fragments are equally perturbed by 
lysosomal dysfunction. Herein, we used a H4 human neuroglioma cell line stably expressing a GFP-tagged 
amyloidogenic version of APP (APP-GFP), which we previously used to facilitate the detection of C99 in the 
form of C99-GFP (33, 40). We tested the effect of chloroquine (CQ) and bafilomycin A1 (BfaA1) on the levels 
of APP-GFP, C99-GFP and C83-GFP (Fig. 1A). CQ and BfaA1 are two drugs that raise organelle pH in the late 
secretory pathway, resulting in perturbation of both endosomal maturation and lysosomal function (41). 
Western blot analysis showed that treatment with CQ or BfaA1 led to a significant ∼2.4-fold or ∼2.1-fold 
increase in APP levels, respectively, compared to non-treated cells (Fig. 1B, lanes 1, 3 and 5, and Fig. 1C). To 
detect C99-GFP and C83-GFP, we treated cells with DAPT, a specific γ-secretase inhibitor (42). As expected, 
western blot analysis using the WO2 antibody (that distinguishes between C99 and C83; Fig. 1A) (43) showed 
that incubation with DAPT alone caused a steady state accumulation of C99-GFP (Fig. 1B, lanes 1 and 2). We 
observed that in the presence of DAPT the treatment with CQ caused a significant ∼1.8-fold increase in C99-
GFP levels, compared to cells treated with DAPT alone (Fig. 1B, lanes 2 and 4, and Fig. 1C). Likewise, 
treatment with BfaA1 in the presence of DAPT caused a significant ∼3.0-fold increase in C99-GFP levels (Fig. 
1B, lanes 2 and 6, and Fig. 1C). In contrast, we found that in the presence of DAPT the treatment with CQ or 
BfaA1 led to a significant decrease of C83-GFP to ∼55% or ∼45%, respectively, of the levels found in control 
cells (Fig. 1B, lanes 2, 4 and 6, and Fig. 1C). In addition, we found that a combination of BfaA1, E64 and 
leupeptin, a cocktail that strongly perturbs lysosomal function (44), increased the levels of endogenous C99 
(Fig. S1). Together, these results indicate that impaired lysosomal function causes a differential effect on the 
CTFs, suggesting that C99 could be a better substrate of lysosomes.  
 
Depletion of TSG101 increases the levels of APP, CTFs, and the number of autophagosomes 
Several studies propose that APP is normally sorted into ILVs of MVBs, and that this process is dependent on 
the ESCRT machinery (26, 28, 29). Although these studies demonstrated that depletion of the ESCRT-0 subunit 
HRS, or of the ESCRT-I subunit TSG101, block APP sorting into ILVs, it is still a matter of discussion if these 
disturbances promote amyloidogenic processing (28, 29), or reduce Aβ production (26). Therefore, we 
evaluated whether the formation of MVBs was important for lysosomal degradation of C99. For this, we 
investigated the effect of depleting TSG101 by RNAi in H4 cells expressing the amyloidogenic version of APP-
GFP. Western blot analysis showed that siRNA-mediated depletion of TSG101 led to a significant increase in 
APP-GFP levels, compared to a non-targeting siRNA (siNT), detected both in the absence or presence of DAPT 
(Fig. 2, A and B). As expected, DAPT caused a steady state accumulation of both C99-GFP and C83-GFP in 
 9 
cells transfected with siNT (Fig. 2A, lanes 1 and 2). In the presence of DAPT, we detected that TSG101 
depletion caused a significant increase in the levels of C99-GFP and C83-GFP compared to control cells (Fig. 
2A, lanes 2 and 4, and Fig. 2B). This result suggests that the degradation of CTFs is greatly enhanced when the 
MVB pathway is functioning normally. 
 
To study whether the depletion of TSG101 affected APP-GFP or CTFs localization, we performed a confocal 
microscopy analysis. In different cell types, including H4 cells, a large proportion of the steady-state 
distribution of endogenous APP is in early endosomes (26, 45). Similarly, in H4 cells the majority of APP-GFP 
localizes in early endosomes (25). Consistent with this notion, we found that in cells transfected with siNT little 
APP-GFP colocalized with LAMP1, a late endosome/MVB/lysosome protein (Fig. S2, A-C and G-H). In 
contrast, depletion of TSG101 resulted in a significant redistribution of APP to enlarged, LAMP1-containing 
endo-lysosomal compartments (Fig. S2, D-H). We obtained similar results with RNAi-mediated depletion of 
HRS (data not shown). Together, these findings suggested that impaired MVB formation caused accumulation 
of APP and CTFs in altered endo-lysosomal compartments. 
 
Because MVBs eventually fuse with autophagosomes (17), we hypothesized that increased levels of APP and 
CTFs in TSG101 depleted cells could be the result of autophagosome accumulation. Therefore, we analyzed by 
confocal fluorescence microscopy the presence of puncta containing the protein p62. During autophagy, these 
puncta recruit specific ubiquitylated cargos by binding to the ubiquitin-associated (UBA) domain of p62 (46), 
puncta that accumulate when the fusion of autophagosomes with endo-lysosomal compartments is blocked (47). 
We found that H4 cells depleted of TSG101 showed a significant increase in the number of puncta containing 
p62, compared to cells treated with siNT (Fig. S3, A, D, and G), in agreement with the effect of a similar 
treatment in HeLa cells (22). A classical marker of autophagosomes is the protein LC3 (47), and accordingly we 
found a significant colocalization of p62-containing puncta with LC3 (Fig. S3, D-F, and N), compared to the 
negligible colocalization of p62-containing puncta with the lysosomal protein Cathepsin D (Fig. S3, K-N). 
These results indicate that TSG101 depletion precludes autophagy-flux and hence this effect could be the cause 
of APP-GFP and CTFs accumulation. To further analyze whether the accumulation of APP-GFP and the CTFs 
is produced when autophagosomes are accumulated, we studied the effect of thapsigargin, a drug that inhibits 
the fusion of autophagosomes to lysosomes (48). As expected, we found that cells treated with thapsigargin also 
accumulated p62-containing puncta (Fig. S4, A and E), similar to the effect reported for MEFs cells (48). 
Moreover, we observed a significant higher colocalization of the p62-containing puncta with LC3, compared to 
that with Cathepsin D (Fig. S4, A-J), indicating that thapsigargin is also a potent inhibitor of autophagy-flux in 
H4 cells. Western blot analysis showed that thapsigargin caused a significant increase in the levels of both APP-
GFP and C99-GFP, but with no apparent effect in the levels of C83-GFP (Fig. S4, K and L), suggesting that the 
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disruption of autophagy-flux by thapsigargin affects differentially the turnover of APP species. Nevertheless, 
because the treatment with thapsigargin can also result in stress of the endoplasmic reticulum (ER) (49), we also 
analyzed the effect of the treatment with Vps34-IN1, which is a selective inhibitor of Vps34, a class III 
phosphatidylinositol 3-kinase that is required for autophagosome formation (50, 51). As expected, 
immunofluorescence analysis showed both that nutrient starvation by incubating cells in EBSS resulted in 
accumulation of puncta that contained LC3 and p62 (Fig. 3, A-F), and that the treatment with Vps34-IN1 of 
cells incubated in complete medium did not accumulate puncta containing LC3 or p62 (Fig. 3, G-I). In contrast, 
the treatment with Vps34-IN1 of cells incubated in EBSS reduced significantly the accumulation of puncta 
containing LC3 and p62 (Fig. 3, J-M), confirming that Vps34-IN1 is a potent blocker of autophagosome 
biogenesis (52). Additional confirmation of the effect of Vps34-IN1 was obtained by western blot analysis that 
showed a time-dependent increase in the levels of LC3-I, and a corresponding decrease in the levels of LC3-II, 
which is the lipidated form of LC3 that decorates autophagosomes (53) (Fig. 3N). Interestingly, the treatment 
with Vps34-IN1 caused a time-dependent increase in the levels of endogenous C99, although with no apparent 
effect on the levels of endogenous APP or C83 (Fig. 3N). Altogether, our results indicate that different 
treatments that disrupt autophagy lead to C99 accumulation. 
 
Depletion of Atg5 accumulates endogenous CTFs in the lumen of enlarged MVBs 
Atg5 conjugated to Atg12 is part of a protein complex that also contains Atg16L, a complex that controls an 
essential step in autophagosome formation (54). Therefore, to further study the contribution of autophagosomes 
in the clearance of APP/CTFs, we analyzed by western blot the steady-state levels of endogenous APP and 
CTFs in H4 cells stably depleted of Atg5 by shRNA-mediated RNAi. We found that cells stably expressing a 
shRNA targeting Atg5 (shAtg5) the levels of APP were significantly decreased to ∼50% the levels found in 
cells expressing a control shRNA (shLuc; Fig. 4A, lanes 1 and 3, and Fig. 4B). We observed a similar result in 
cells treated with DAPT (Fig. 4A, lanes 2 and 4, and Fig. 4C), indicating that decreased APP levels were not the 
result of increased γ-secretase activity. Moreover, we found that in contrast to control cells, the levels of APP in 
Atg5 depleted cells were not rescued with the combination of BfaA1, E64 and leupeptin (Fig. S5), indicating 
that the decreased level of APP in Atg5 depleted cells was not the result of an increase in APP degradation. On 
the other hand, we observed a significant ∼3.9-fold increase in C99 levels in Atg5 depleted cells (Fig. 4A, lanes 
1 and 3, and Fig. 4B). We also observed a significant ∼23.1-fold increase in C83 levels in Atg5 depleted cells 
(Fig. 4A, lanes 1 and 3, and Fig. 4B). These observations strongly indicate that perturbation of Atg5-dependent 
autophagy results in augmented proteolytic processing of APP, with generation of CTFs that ultimately 
accumulate. 
To evaluate the possible effect of the γ-secretase activity on the levels of CTFs in Atg5 depleted cells we treated 
cells with DAPT. Treatment of control cells with DAPT resulted in increased levels of both, C99 and C83 (Fig. 
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4A, lanes 1 and 2), indicative of the expected γ-secretase activity on the CTFs. In Atg5 depleted cells treatment 
with DAPT also resulted in a significant increase in the levels of both CTFs (Fig. 4A, lanes 3 and 4, and Fig. 
4C). However, when comparing the treatment with DAPT between control and Atg5-depleted cells we observed 
that the levels of C99 underwent the most significant increase: ∼7.9-fold increase of C99 versus ∼2.0-fold 
increase of C83 (Fig. 4A, lanes 2 and 4, and Fig. 4D). These results are consistent with the notion that impaired 
autophagosome formation caused increased amylodogenic processing of APP. 
To determine the effect that Atg5 depletion could have on the intracellular localization of APP and CTFs, we 
performed immunofluorescence analysis using an antibody targeting the C-terminal, cytosolic domain of APP 
(anti-Tail; Fig. 1A), and examined cells by confocal microscopy. Consistent with the localization of APP-GFP, 
we found that in control H4 cells little endogenous APP/CTFs localized in MVBs/lysosomes decorated with 
antibody to LAMP1, and that a higher proportion localized instead in early endosomes decorated with antibody 
to EEA1 (Fig. 5, A-D, and I-L). In contrast, Atg5 depletion led to a significant ∼3.0-fold increase in the 
colocalization of APP/CTFs with LAMP1, and a corresponding significant decrease in the colocalization with 
EEA1 to ∼45% the levels found in control cells (Fig. 5, E-H, and I-L). Similarly, we observed that depletion of 
Atg5 led to a significant ∼2.6-fold increase in APP/CTFs colocalization with Cathepsin D, while the expected 
colocalization of Cathepsin D with LAMP1 remained largely unaffected (Fig. S6, B-C, F-G, K and M). On the 
other hand, quantification of fluorescence intensity showed a significant ∼4.6-fold increase in the levels of 
APP/CTFs in Atg5 depleted cells (Fig. 5M). This last result correlates with the western blot analysis (Fig. 4A), 
and further supports the conclusion that Atg5 depletion causes a massive increase in APP/CTFs levels in 
organelles positive to LAMP1 and Cathepsin D. Because the anti-Tail antibody recognizes the cytosolic domain 
of APP and both CTFs, the APP species that accounts for the increase in fluorescence intensity cannot be 
discriminated. Nevertheless, the western blot analysis suggests that the majority of the fluorescence signal 
corresponded to CTFs. We also observed that in cells depleted of Atg5 the organelles decorated with antibodies 
to LAMP1 or Cathepsin D were enlarged, and were mainly localized at the perinuclear region (Fig. 5, B and F, 
and Fig. S6, B and F), in agreement with a previous study performed in mouse embryonic fibroblasts (55), 
suggesting that depletion of Atg5 caused a disruption of MVBs/lysosomes. Accordingly, these Cathepsin D and 
LAMP1-positive large organelles were also positive to CD63 (Fig S7, A-F) and to LAMP2 (Fig. S7, G-L), both 
proteins also localized mainly in MVBs/lysosomes (56, 57), and that similar to the colocalization of Cathepsin 
D with LAMP1, the colocalization of Cathepsin D with CD63 or LAMP2 was unaffected in cells depleted of 
Atg5 (Fig S7, M and N). All these results strongly suggest that Atg5 depletion perturbs the homeostasis of 
MVBs/lysosomes, condition that enhances the accumulation of intracellular CTFs. 
 
To analyze in more detail the organelles that accumulate CTFs in Atg5 depleted cells we used super resolution, 
structured illumination microscopy (SIM). As shown by standard confocal microscopy (Fig. 5, A-C), most of 
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the APP/CTFs fluorescent signal in control cells was detected in cytoplasmic structures that were different to 
MVBs/lysosomes decorated with antibody to LAMP1 (Fig. 6, A-C). However, the APP/CTFs fluorescent signal 
in Atg5 depleted cells was detected in structures resembling ILVs of enlarged LAMP1-containing MVBs (Fig. 
6, D-G). Moreover, fluorescence intensity analysis of SIM images showed that the APP/CTFs signal is 
restricted to the lumen of enlarged LAMP1-containing organelles and therefore excluded from their limiting 
membrane, suggesting that APP/CTFs were efficiently sorted into ILVs (Fig. 6, G-H). These results indicate 
that accumulation of APP/CTFs in Atg5 depleted cells was not due to impaired incorporation of APP/CTFs into 
ILVs. Together, this suggests that APP/CTFs are sorted into ILVs of MVBs en route to lysosomes for 
degradation.  
 
Activation of autophagy promotes intracellular clearance of C99 
Our results showed that autophagosomes are necessary for the clearance of intracellular CTFs via the endo-
lysosomal pathway. To directly examine the active role of autophagy in C99 clearence, we subjected H4 cells 
stably expressing C99-GFP to nutrient starvation by incubation in EBSS, an established treatment that activates 
autophagy (16). Western blot analysis showed that nutrient starvation led to a significant, time-dependent 
reduction in C99-GFP levels, as well as of AICDγ-GFP (Fig. 7, A and B). Likewise, treatment with Torin-1, a 
potent and selective inhibitor of mTORC1/2 that also activates macroautophagy (58), similarly reduced C99-
GFP and AICDγ-GFP levels in a time-dependent manner (Fig. 7, C and D). Treatment with either EBSS or 
Torin-1 in the presence of DAPT did not prevent the reduction of both C99-GFP and AICDγ-GFP levels (Fig. 7, 
E and F), indicating that the reduction in the levels of C99-GFP was not the result of γ-secretase activity. These 
last results strongly indicate that autophagy can participate in the clearance of amyloidogenic APP fragments. 
All the results shown in the present report are consistent with a model of a concerted function of 
autophagosomes and the MVB pathway for the clearance of amyloidogenic C99. 
 
DISCUSSION 
Several lines of evidence indicate that defects in long-term potentiation and cognitive impairment correlate 
better with increased intracellular Aβ-like immunoreactivity than with the presence of extracellular Aβ 
aggregates (59-61). The analysis of a murine model of AD (3xTgAD mice) showed that intracellular 
accumulation of early and age-dependent Aβ-like species corresponds to C99 rather than full-length APP or the 
Aβ peptide (59). Thus, C99 seems to be the earliest initiator of synaptic plasticity and long-term memory 
impairment in AD (62), presumably due to its early accumulation at the hippocampus (59, 61).  
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Although the cause of C99 accumulation remains unknown, several early studies point-out abnormalities of 
endo-lysosomal compartments within neurons located in affected brain regions of patients with AD (7, 14). The 
abnormalities include an increased number of endo-lysosomal compartments, particularly in the cell soma of 
pyramidal neurons (7). Of note, the dependence of neuronal function on the endo-lysosomal system is well 
documented because of the existence of many lysosomal primary disorders, in which defects in lysosomal 
function cause severe neurodegeneration phenotypes (63), including pathological features of AD (64). 
 
Early accumulation of C99 in enlarged endo-lysosomal neuronal compartments of 3xTgAD mice suggests an 
impaired clearance of C99 by the endo-lysosomal system (59). In fact, it has been proposed that depletion of 
some ESCRT subunits inhibits APP sorting into ILVs of MVBs (26, 28, 29). In agreement with this, we found 
that TSG101 depletion in H4 cells caused an increase in APP-GFP levels detected by western blot analysis, 
which correlated with accumulation of APP-GFP in enlarged endo-lysosomal compartments decorated with 
antibodies to LAMP1. Moreover, we found that TSG101 depletion increased CTFs levels, suggesting that CTFs 
are also sorted into ILVs. We also observed a robust increase in the levels of C99-GFP and endogenous C99 in 
response to treatments that perturb lysosomal function, supporting the conclusion that lysosomes are implicated 
in C99 clearance, as well as in APP turnover (26, 33, 61). Moreover, perturbed lysosomal function led to a 
significant decrease in C83-GFP levels. These results indicate that proper lysosomal function favor the non-
amyloidogenic processing of APP preventing the accumulation of C99. Interestingly, TSG101 depletion results 
in accumulation of APP/CTFs in an endo-lysosomal compartment that appears to contain proteins of both early 
endosomes and MVBs/lysosomes, such as EEA1 and LAMP1, respectively (26, 28, and the present study), 
emphasizing the need of normal maturation of early endosomes into MVBs to avoid accumulation of 
amyloidogenic proteins. 
 
In addition to the evidence showing that APP is sorted to the endo-lysosomal pathway for delivery to lysosomes 
(25, 26, 28, 33), other findings indicate that the cellular levels of both APP and C99 are also regulated by 
autophagy (31, 32, 34). However, the contribution of both pathways in the total clearance of these 
amyloidogenic membrane proteins remains unknown. In this regard, different reports indicate that the endo-
lysosomal system is functionally connected to autophagy (10, 17, 18, 23). In fact, autophagosomes can fuse to 
MVBs prior to lysosome delivery (18). Moreover, depletion of some ESCRT subunits accumulates 
autophagosomes by precluding their fusion to MVBs or lysosomes (22, 30, 65). In the present study, we show 
that, similar to HeLa cells (22), TSG101 depletion in H4 cells also inhibited autophagy-flux. We found that 
TSG101 depletion resulted in accumulation of APP species in endo-lysosomal organelles containing LAMP1. 
To distinguish between autophagy-flux inhibition and impaired sorting into ILVs of MVBs as the cause of APP 
and CTFs accumulation in TSG101 depleted cells, we investigated the effect of treatment with thapsigargin. 
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Thapsigargin is a classical stressor of the ER (66) that also blocks the fusion of autophagosomes to endo-
lysosomal compartments, but by hampering recruitment of Rab7 to autophagosomes, a critical step during 
macroautophagy (48). Treatment with thapsigargin resulted in impaired autophagy-flux and increased APP and 
C99 levels, which is consistent with the notion that autophagy is critical for APP/CTFs clearance. In addition, 
we found increased levels of endogenous C99 upon selective inhibition of Vps34, which is a kinase that 
produces phosphatidylinositol-3-phosphate (PI3P), a crucial lipid for autophagosome nucleation and maturation 
(50, 51). This result is in agreement with a previous report showing that silencing of Vps34 enhances the 
production of Aβ in primary mouse cortical neurons (29). Because inhibition of Vps34 also resulted in 
inhibition of both basal autophagy and autophagy induced by nutrient starvation, the higher levels of Aβ peptide 
in cells depleted of Vps34 could be consequence of impairment in the MVB/lysosomal pathway due to 
perturbed autophagosome biogenesis. Together, these results suggest that autophagosomes are necessary for the 
degradation of C99 in the MVB/lysosomal pathway. Thus, increased CTFs levels in LAMP1-containing 
organelles during impaired, basal Atg5-dependent autophagy provide additional support to the notion that 
autophagy-flux is necessary for C99 clearance. Moreover, our SIM analysis in Atg5 depleted cells strongly 
suggests that accumulation occurred in ILVs of enlarged MVBs. 
 
Because the fusion between an autophagosome and an MVB is the convergence point between these two 
pathways (17, 18), our findings indicate that upon Atg5-dependent autophagy-impairment the MVB/lysosomal 
pathway could be dramatically affected, and hence the degradation of cargos such as APP/CTFs. In this regard, 
we showed that Atg5 depletion caused an apparent accumulation of CTFs in perinuclear, enlarged organelles 
positive to LAMP1, as well as positive to CD63, LAMP2 and Cathepsin D, suggesting that a dramatic effect on 
the maturation of MVBs affected the degradation of CTFs. In contrast, recent studies in murine models of 
Down syndrome and Alzheimer's disease show that C99 accumulates in enlarged early endosomes that contain 
over activated Rab5 (67-69), suggesting the intriguing possibility that in those cases a similar mechanism of 
inter organelle fusion is impaired, although is not well known whether or not autophagosomes can fuse to early 
endosomes (70, 71). Nevertheless, our immunofluorescence analysis to EEA1 showed no apparent differences 
in the morphology of early endosomes in control and Atg5 depleted cells. In addition, we observed a reduction 
in the colocalization of APP/CTFs and EEA1 upon Atg5 depletion, suggesting that perturbations at different 
levels of the endo-lysosomal system could lead to a similar outcome of C99 accumulation. Likewise, it will be 
important to determine if an initial accumulation of C99 triggers the enlargement of endo-lysosomal organelles 
affecting their functions. In any case, our results provide strong evidence that autophagosomes cooperate in 
maintaining reduced levels of C99 either indirectly, by avoiding C99 production in MVBs, or directly, by 
accelerating C99 degradation in autolysosomes. 
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Our findings suggested that Atg5 depletion also elicited processing of APP into both C99 and C83. A likely 
explanation is that APP being accumulated in enlarged MVBs was subsequently processed by α-secretases 
and/or BACE-1. This is in agreement with the popular idea that amyloidogenic processing of APP occurs 
mainly in endosomes (72). A different scenario is that APP could have been processed in a pre-endo-lysosomal 
compartment, such as the ER or the Golgi apparatus, and that the resulting products C83 and C99 accumulated 
in MVBs. Although less popular, the possibility of amyloidogenic processing in a pre-endosomal compartment 
is supported by several reports (25, 73). However, the finding that Atg5 depleted cells presented a 
disproportionate increase of C83 indicates that macroautophagy also plays an important but unexpected role in 
the nonamylodogenic processing of APP. 
 
Our data allow us to propose that autophagosomes have an important function in APP and CTFs proteostasis. 
Our proposal is consistent with the observation that autophagosomes gradually accumulate in dystrophic 
neurites; a well-documented neuropathological hallmark of AD (14). Autophagy has been proposed as an 
essential activity for neuronal survival, acting as a neuroprotective process activated to alleviate cellular stress 
(9). In the nervous system a major negative regulator of autophagy is the serine/threonine kinase mTOR, 
therefore it is plausible that its inhibition would reduce the burden caused by deleterious accumulation of 
intracellular materials. In support of this notion is the observation that reduced mTOR signaling extends the 
lifespan of model organisms and protects them against age-related pathologies, including AD (74, 75). Our 
finding that autophagy activation by two conditions that inhibit mTOR signaling, namely by nutrient starvation 
or treatment with Torin-1, reduced the levels of C99 highlights this pathway's potential as a pharmacological 
target.  
 
Collectively, our data support a model in which autophagosomes cooperate in the turnover of C99, as well as of 
APP and C83, forming an amphisome-like compartment by fusing with MVBs prior to fusion with lysosomes 
(Fig. 8). Our model predicts that conditions that compromise the fusion of autophagosomes to endo-lysosomal 
compartments accumulate C99, and thus promote neuronal dysfunction. Further studies will help to clarify 
whether fusion of autophagosomes with MVBs is a frequent process or a specific event, taking place with a 
distinct pool of MVBs, and for the clearance of certain cargos, such as APP and CTFs. As a corollary, failures 
in macroautophagy could impact the balance of proteins that are incorporated into ILVs of MVBs, and therefore 
we propose that the fate of autophagosomes constitutes an inherent part of the membrane flux that exists in the 
endo-lysosomal pathway of protein clearance. Hence, the pharmacological booster of autophagy could promote 
the degradation of C99 and likely of other substrates destined to the endo-lysosomal pathway, emerging as an 
attractive approach for therapeutic intervention of AD, and eventually of other neurodegenerative disorders 
related to protein accumulation. 
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FIGURE LEGENDS 
Figure 1. Lysosomal activity inhibition increases APP-GFP and C99-GFP levels. (A) Schematic 
representation of APP proteolytic processing indicating the N-terminal (N) luminal domain 
(Luminal/Extracellular), transmembrane domain (TM), C-terminal (C) cytosolic domain (Cytosolic), with the 
position of the α, β and γ cleavage sites, the resulting C-terminal fragments C99, C83, and AICDγ, and the Aβ 
and p3 peptides. Lines depict APP regions recognized by the antibodies used in this study (WO2 and Anti-Tail). 
The inhibitory effect of DAPT on γ-secretase activity and the localization of the green fluorescent protein 
(GFP) moiety are also indicated. (B) H4 cells stably expressing an amyloidogenic version of GFP-tagged APP 
were left untreated (lane 1) or treated either with 1 µM DAPT for 16 h (lane 2), 200 µM chloroquine (CQ) for 4 
h (lane 3), 1 µM DAPT for 12 h followed by a combination of 1 µM DAPT and 200 µM CQ for 4 h (lane 4), 
100 nM bafilomycin A1 (BfaA1) for 4 h (lane 5), or 1 µM DAPT for 12 h followed by a combination of 1 µM 
DAPT and 100 nM BfaA1 for 4 h (lane 6). Detergent-soluble protein extracts were analyzed by western blot 
either with anti-GFP (to detect GFP-tagged APP, C83 and AICDγ), the monoclonal antibody WO2 (used to 
show the detection of only C99-GFP), or with anti-β-actin used as a loading control. The position of molecular 
mass markers is indicated on the left. (C) Densitometric quantification of the western blot signal of GFP-tagged 
APP (APP-GFP), C99 (C99-GFP) and C83 (C83-GFP) from cells treated with DAPT alone (Control), or in 
combination with either CQ or BfaA1, as shown in A. Bars represent the mean ± standard deviation of the 
western blot signal normalized with the β-actin signal (n=3). * P < 0.05, ** P < 0.01 and *** P < 0.001.  
 
Figure 2. TSG101 depletion increases the levels of APP species generated from an amyloidogenic version 
of APP-GFP. (A) H4 cells stably expressing an amyloidogenic version of GFP-tagged APP were transfected 
with either a control siRNA (siNT) or a siRNA targeting TSG101 (siTSG101), and further left untreated (lanes 1 
and 3), or treated with 1 µM DAPT for 16 h (lanes 2 and 4). Detergent-soluble protein extracts were analyzed 
by western blot either with anti-GFP (to detect GFP-tagged APP, C99, C83 and AICDγ), the monoclonal 
antibody WO2 (used to show the detection of only C99-GFP; C99-GFP*), or anti-TSG101. Western blot with 
anti-β-actin was used as a loading control. The position of molecular mass markers is indicated on the left. (B) 
Densitometric quantification of the western blot signal of GFP-tagged APP (APP-GFP), C99 (C99-GFP) and 
C83 (C83-GFP) in cells treated with DAPT, as shown in (A). Bars represent the mean ± standard deviation of 
the western blot signal normalized with the β-actin signal (n=3). ** P < 0.01 and *** P < 0.001.  
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Figure 3. Selective inhibition of the class III phosphatidylinositol 3-kinase Vps34 inhibits basal autophagy 
and autophagy induced by nutrient starvation, and increases the levels of endogenous C99. H4 cells were 
left untreated (A-C), or treated either with Earle's balanced salt solution (EBSS) for 1 h (D-F), 1 µM Vps34-IN1 
for 1 h (G-I), or a combination of 1 µM Vps34-IN1 and EBSS for 1 h (J-L). Cells were fixed, permeabilized, 
and incubated with anti-LC3 (A, D, G and J) and with anti-p62 (B, E, H and K), followed by incubation with 
Alexa-488-conjugated donkey anti-rabbit IgG (green channels) and Alexa-594-conjugated donkey anti-mouse 
IgG (red channels). Images were acquired by fluorescence microscopy. Merging green and red channels 
generated the third image in each row; yellow indicates overlapping of the green and red channels. Bar, 10 µm. 
(M) Quantification of the number of LC3- or p62-containing puncta per cell in response to incubation with 
EBSS for 1 h or a combination of 1 µM Vps34-IN1 and EBSS for 1 h. Bars represent the mean ± standard 
deviation (n=10). (N) H4 cells were treated either with 2 µM DAPT (Control) for 16 h (lane 1), with 2 µM 
DAPT for 15 h followed by a combination of 2 µM DAPT and 1 µM Vps34-IN1 for 1 h (lane 2), or with 2 µM 
DAPT for 14 h followed by a combination of 2 µM DAPT and 1 µM Vps34-IN1 for 2 h (lane 3). Detergent-
soluble protein extracts were analyzed by western blot with either an antibody targeting the cytosolic tail of 
APP (to detect APP and C83), the monoclonal antibody WO2 (used to show the detection of only C99), or an 
anti-LC3 antibody that detects both LC3-I and LC3-II. Western blot with anti-β-actin was used as a loading 
control. The position of molecular mass markers is indicated on the left. 
 
Figure 4. Atg5 depletion accumulates C99 and C83. (A) H4 cells stably expressing a control shRNA (shLuc) 
or a shRNA targeting Atg5 (shAtg5) were left untreated (-) or treated (+) with 2 µM DAPT for 16 h. Detergent-
soluble protein extracts were analyzed by western blot with either an antibody targeting the cytosolic tail of 
APP (to detect APP and C83), the monoclonal antibody WO2 (used to show the detection of only C99), or an 
anti-Atg5 antibody that detects the Atg5-Atg12 conjugate. Western blot with anti-β-actin was used as a loading 
control. The position of molecular mass markers is indicated on the left. (B) Densitometric quantification of 
APP, C99 and C83 western blot signals in cells treated without DAPT, as shown in (A). (C) Densitometric 
quantification of APP, C99 and C83 western blot signals in cells treated with DAPT, as shown in (A). (D) 
Densitometric quantification of C99 and C83 western blot signals in Atg5 depleted cells (shAtg5) that were left 
untreated (-) or treated with DAPT (+), as shown in (A). Bars represent the mean ± standard deviation of the 
western blot signal normalized with the β-actin signal (n=3). * P < 0.05, ** P < 0.01. 
 
Figure 5. Atg5 depletion increases the amount of endogenous APP and CTFs localized in an enlarged 
LAMP1-containing endo-lysosomal compartment. (A-H) H4 cells stably expressing either a control shRNA 
(shLuc, A-D) or a shRNA targeting Atg5 (shAtg5, E-H) were fixed, permeabilized, and incubated with an 
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antibody targeting the cytosolic tail of APP (to detect APP, C99, C83 and AICDγ; APP/CTFs; A and E), with 
anti-LAMP1 (B and F), and with anti-EEA1 (C and G), followed by Alexa-488-conjugated donkey anti-rabbit 
IgG (green channels), Alexa-594-conjugated donkey anti-mouse IgG (red channels) and Alexa-647-conjugated 
goat anti-human IgG (blue channels). Images were acquired by laser scanning confocal microscopy. Merging 
green, red and blue channels generated the fourth image in each row; yellow indicates overlapping of the green 
and red channels, cyan indicates overlapping of the green and blue channels, magenta indicates overlapping of 
the red and blue channels, and white indicates overlapping of all channels. Insets show 3x magnifications with 
arrows indicating colocalization of APP/CTFs and EEA1 in shLuc cells or colocalization of APP/CTFs and 
LAMP1 in shAtg5 cells. Bar, 10 µm. (I) Quantification of the fluorescence signal of APP/CTFs that colocalized 
with the fluorescence signal of LAMP1, from images as shown in A and B of control cells (shLuc), or as shown 
in E and F of Atg5 depleted cells. (J) Quantification of the fluorescence signal of APP/CTFs that colocalized 
with the fluorescence signal of EEA1, from images as shown in A and C of control cells (shLuc), or as shown in 
E and G of Atg5 depleted cells. Bars represent the mean ± standard deviation (n=12). (K and L) Scatter plot 
graphs with Pearson's correlation coefficients obtained from the colocalization analysis shown in I and J. (M) 
Quantification of the fluorescence intensity of APP species shown in A and E. Bars represent the mean ± 
standard deviation of the fluorescent signal per cell area (n=12). *** P ≤ 0.001.  
 
Figure 6. Super resolution microscopy revealed that Atg5 depletion accumulates APP/CTFs in the lumen 
of enlarged LAMP1-containing endo-lysosomal compartments. (A-G) H4 cells stably expressing either 
control shRNA (shLuc, A-C) or a shRNA targeting Atg5 (shAtg5, D-G) were fixed, permeabilized, and 
incubated with an antibody targeting the cytosolic tail of APP (to detect APP, C99, C83 and AICDγ; 
APP/CTFs; A, D and G) and anti-LAMP1 (B, E and G), followed by Alexa-488-conjugated donkey anti-rabbit 
IgG (green channels) and Alexa-594-conjugated donkey anti-mouse IgG (red channels). Nuclei were stained 
with DAPI (blue channels). Images were acquired by structured illumination microscopy. Merging green, red 
and blue channels generated the third image in the first two rows. The image shown in G is a composite of the 
green and red channels of a threefold magnified region representative of an image similar to that shown in F. 
Bars: A-F, 1 µm; G, 200 nm. (H) Graph representing a scan of the fluorescence signal of APP/CTFs and 
LAMP1 along the dashed line shown in (G). 
 
Figure 7. Activation of autophagy by nutrient starvation and Torin-1 treatments decreases C99 levels. (A 
and C) H4 cells stably expressing an amyloidogenic version of GFP-tagged C99 were incubated with Earl's Salt 
Balance Solution (EBSS; A), or with 250 nM Torin-1 (C), for the indicated periods of time. Detergent-soluble 
protein extracts were analyzed by western blot with anti-GFP (to detect GFP-tagged C99 and AICDγ). Western 
blot with anti-β-actin was used as a loading control. The position of molecular mass markers is indicated on the 
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left. (B and D) Densitometric quantification of C99-GFP and AICDγ-GFP western blot signals, at time = 0 
(Control) and after 4 h of treatment either with EBSS (B) (as shown in A), or with Torin-1 (D) (as shown in C). 
Bars represent the mean ± standard deviation of the western blot signal normalized with the β-actin signal 
(n=3). (E) Alternatively, cells were left untreated (lane 1), or treated with 2 µM DAPT for 16 h (lanes 2, 3 and 
5), or treated with 2 µM DAPT for 12 h followed by either a combination of 2 µM DAPT and EBSS for 4 h 
(lane 4), or a combination of 2 µM DAPT and 250 nM Torin-1 for 4 h (lane 6). (F) Densitometric quantification 
of the C99-GFP western blot signal in cells treated with DAPT alone (Control), or in combination with either 
EBSS or Torin-1, as shown in (E). Bars represent the mean ± standard deviation of the amount of western blot 
signal normalized with the β-actin signal (n=3). ** P < 0.01. 
 
Figure 8. Model of the mechanism underlying the turnover of APP and CTFs via Atg5-dependent 
macroautophagy. APP, C99 and C83 can reach an early endosome either (1) via the trans-Golgi network 
(TGN), or (2) via the cell surface. (3) An early endosome matures to a late endosome, also called a 
multivesicular body (MVB). (4) APP, C99 and C83 are incorporated into intraluminal vesicles of an MBV in a 
process facilitated by the ESCRT machinery (ESCRT-0 - ESCRT-III), in which TSG101 is part of ESCRT-I. (5) 
In parallel, the Atg5-Atg12-Atg16L complex facilitates LC3 lipidation (LC3-I) with phosphatidylethanolamine. 
(6) Lipidated LC3 (LC3-II) associates to a pre-autophagosomal membrane called a phagophore, a process that 
promotes recruitment of autophagy cargos and adaptor proteins, such as p62. (7) The phagophore matures to 
form an autophagosome, a double-membrane-bound organelle. (8) An autophagosome can fuse with endo-
lysosomal compartments, such as a MVB. The fusion of an autophagosome with a MVB results in the 
formation of a hybrid organelle called amphisome. (9) An amphisome can fuse with a lysosome promoting the 
final degradation of APP, C99 and C83.  
 
Figure S1. Lysosomal activity inhibition increases the levels of endogenous C99. H4 cells were left 
untreated (lane 1), or treated either for 4 h with a cocktail of lysosomal inhibitors composed of 100 nM 
bafilomycin A1 (BfaA1), 10 µM E64D, and 70 µg/ml leupeptin (lane 2), or for 16 h with 2 µM DAPT (lane 3), 
or for 12 h with 2 µM DAPT followed by 4 h with a combination of 2 µM DAPT and the cocktail of lysosomal 
inhibitors (lane 4). Detergent-soluble protein extracts were analyzed by western blot with the monoclonal 
antibody WO2. Western blot with anti-β-actin was used as a loading control. The position of molecular mass 
markers is indicated on the left.  
 
Figure S2. TSG101 depletion produces APP-GFP accumulation in enlarged LAMP1-containing endo-
lysosomal compartments. (A-F) H4 cells stably expressing an amyloidogenic version of GFP-tagged APP 
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(green channel) were transfected with either a control siRNA (siNT; A-C) or a siRNA targeting TSG101 
(siTSG101; D-F). After 48 h, cells were fixed, permeabilized, and incubated with anti-LAMP1, followed by 
incubation with Alexa-594-conjugated donkey anti-mouse IgG (red channel). Images were acquired by laser 
scanning confocal microscopy. Merging green and red channels generated the third image in each row; yellow 
indicates overlapping of the green and red channels. Bar, 10 µm. (G) Quantification of the fluorescence signal 
of APP-GFP species that colocalized with the fluorescence signal of LAMP1, from images as shown in A-E. 
Bars represent the mean ± standard deviation (n=12). (H) Scatter plot graph with Pearson's correlation 
coefficients obtained from the colocalization analysis shown in (G). *** P < 0.001.  
 
Figure S3. TSG101 depletion produces accumulation of p62- and LC3-containing puncta. (A-M) H4 cells 
were transfected with either a control siRNA (siNT; A-C and H-J) or a siRNA targeting TSG101 (siTSG101; D-
F and K-M). After 72 h, cells were fixed, permeabilized, and co-incubated either with anti-p62 (A and D) and 
anti-LC3 (B and E), or with anti-p62 (H and K) and anti-Cathepsin D (I and L), followed by Alexa-594-
conjugated donkey anti-mouse IgG (red channels) and Alexa-488-conjugated donkey anti-mouse IgG (green 
channels). Nuclei were stained with DAPI (blue channels). Images were acquired by laser scanning confocal 
microscopy. Merging red, green and blue channels generated the third image in each row. Bars, 10 µm. (G) 
Quantification of the number of p62-containing puncta per cell. Bars represent the mean ± standard deviation 
(n=10). (N) Colocalization analysis of images from cells transfected with the siRNA targeting TSG101. The 
graph depicts the quantification of the fluorescence signal of either LC3 or Cathepsin D (Cat D) that colocalized 
with the fluorescence signal of p62, from images as shown in D and E, and K and L, respectively. Bars 
represent the mean ± standard deviation (n=12). *** P < 0.001. 
 
Figure S4. Thapsigargin treatment produces accumulation of p62- and LC3-containing autophagosomes, 
and increases the levels of GFP-tagged APP species. (A-H) H4 cells were left untreated or treated with 2 µM 
thapsigargin for 16 h. Cells were fixed, permeabilized, and incubated with antibodies targeting p62 (A and E), 
LC3 (B and F) or Cathepsin D (C and G), followed by Alexa-594-conjugated donkey anti-mouse IgG (red 
channels), Alexa-488-conjugated donkey anti-rabbit IgG (green channels), and Alexa-647-conjugated donkey 
anti-goat IgG (blue channels). Images were acquired by epifluorescence microscopy. Merging green, red and 
blue channels generated the fourth image in each row; yellow indicates overlapping of the green and red 
channels. Bar, 10 µm. (I and J) Colocalization analysis of images from cells treated with thapsigargin. In I the 
graph depicts the quantification of the fluorescence signal of p62 that colocalized with the fluorescence signal 
of either LC3 or Cathepsin D, from images as shown in E and F, or in E and G, respectively, and the 
quantification of the fluorescence signal of LC3 that colocalized with the fluorescence signal of Cathepsin D, 
from images as shown in F and G. Bars represent the mean ± standard deviation (n=12). In J the graph depicts a 
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scatter plot with Pearson's correlation coefficients obtained from the colocalization analysis shown in I. *** P < 
0.001. (K) H4 cells stably expressing an amyloidogenic version of GFP-tagged APP were treated with 2 µM 
DAPT for 16 h (lane 1) or with a combination of 2 µM DAPT and 2 µM thapsigargin for 16 h (lane 2). 
Detergent-soluble protein extracts were analyzed by western blot either with anti-GFP (to detect GFP-tagged 
APP and C83), the monoclonal antibody WO2 (used to show the detection of only C99-GFP), or anti-β-actin 
(used as loading control). The position of molecular mass markers is indicated on the left. (L) Densitometric 
quantification of the western blot signal of GFP-tagged APP species, as shown in K. Bars represent the mean ± 
standard deviation of the amount of immunoblot signal normalized with the β-actin signal (n=3). ** P < 0.01; 
n.s., not statistically significant. 
 
Figure S5. Reduced endogenous APP levels in cells depleted of Atg5 are not rescued by inhibitors of 
lysosomal degradation. H4 cells stably expressing a control shRNA (shLuc) or a shRNA targeting Atg5 
(shAtg5) were left untreated (lanes 1 and 4) or treated 4 or 8 hours (h) with a cocktail of lysosomal inhibitors 
composed of 50 nM bafilomycin A1 (BfaA1), 10 µM E64D, and 70 µg/ml leupeptin. Detergent-soluble protein 
extracts were analyzed by western blot with an antibody targeting the cytosolic tail of APP. Western blot with 
anti-β-actin was used as a loading control. The position of molecular mass markers is indicated on the left. 
 
Figure S6. Atg5 depletion increases the amount of endogenous APP and CTFs localized in an enlarged 
endo-lysosomal compartment containing LAMP1 and Cathepsin D. (A-H) H4 cells stably expressing either 
a control shRNA (shLuc, A-D) or a shRNA targeting Atg5 (shAtg5, E-H) were fixed, permeabilized, and 
incubated with antibodies targeting either the cytosolic tail of APP (to detect APP, C99, C83 and AICDγ; 
APP/CTFs; A and E), LAMP1 (B and F) or Cathepsin D, followed by Alexa-488-conjugated donkey anti-rabbit 
IgG (green channels), Alexa-594-conjugated donkey anti-mouse IgG (red channels) and Alexa-647-conjugated 
donkey anti-goat IgG (blue channels). Images were acquired by laser scanning confocal microscopy. Merging 
green, red and blue channels generated the fourth image in each row; white indicates overlapping of the green, 
red and blue channels. Bar, 10 µm. (I) Quantification of the fluorescence signal of APP/CTFs that colocalized 
with the fluorescence signal of LAMP1, from images as shown in A and B of control cells (shLuc), or as shown 
in E and F of Atg5 depleted cells. (J) Quantification of the fluorescence signal of APP/CTFs that colocalized 
with the fluorescence signal of Cathepsin D, from images as shown in A and C of control cells (shLuc), or as 
shown in E and G of Atg5 depleted cells. (K) Quantification of the fluorescence signal of Cathepsin D (CatD) 
that colocalized with the fluorescence signal of LAMP1, from images as shown in B and C of control cells 
(shLuc), or as shown in F and G of Atg5 depleted cells. Bars represent the mean ± standard deviation (n=12). (L 
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and M) Scatter plot graphs with Pearson's correlation coefficients obtained from the colocalization analysis 
shown in J and K. 
 
 
Figure S7. Atg5 depletion caused the appearance of perinuclear enlarged organelles decorated with 
antibody to Cathepsin D, CD63 and LAMP2. (A-L) H4 cells stably expressing either a control shRNA 
(shLuc, A-C and G-I) or a shRNA targeting Atg5 (shAtg5, D-F and J-L) were fixed, permeabilized, and 
incubated with antibodies targeting either Cathepsin D (A, D, G and J), CD63 (B and E), or LAMP2 (H and K), 
followed by Alexa-488-conjugated donkey anti-goat IgG (green channels), and Alexa-594-conjugated donkey 
anti-mouse IgG (red channels). Images were acquired by laser scanning confocal microscopy. Merging green 
and red channels generated the third image in each row; yellow indicates overlapping of the green and red 
channels. Bar, 10 µm. (M) Quantification of the fluorescence signal of Cathepsin D that colocalized with the 
fluorescence signal of CD63, from images as shown in A and B of control cells (shLuc), or as shown in D and E 
of Atg5 depleted cells. (N) Quantification of the fluorescence signal of Cathepsin D that colocalized with the 
fluorescence signal of LAMP2, from images as shown in G and H of control cells (shLuc), or as shown in J and 
K of Atg5 depleted cells. Bars represent the mean ± standard deviation (n=12). (O and P) Scatter plot graphs 
with Pearson's correlation coefficients obtained from the colocalization analysis shown in M and N. 
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